^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ojemda (tovorafenib)

    i
    Company:
    Day One Biopharma, Ipsen, Takeda, Xoma
    Drug class:
    pan-RAF inhibitor
    Related drugs:
    Apply
    A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis (NCT05828069)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    03/28/2024
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    BRAF • ALK • ERBB3
    |
    BRAF V600E • BRAF V600 • ERBB3 mutation
    |
    Ojemda (tovorafenib)
    DAY101 In Gliomas and Other Tumors (PNOC014) (NCT03429803)
    Phase 1
    Karen D. Wright, MD
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    02/27/2018
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    NF1
    |
    Ojemda (tovorafenib)
    Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas (VICTORY) (NCT06381570)
    Phase 1
    Daniel Morgenstern
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    03/21/2024
    Primary completion :
    03/21/2026
    Completion :
    03/21/2029
    BRAF
    |
    Ojemda (tovorafenib) • vinblastine
    Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors (FIRELIGHT-1) (NCT04985604)
    Phase 1/2
    Day One Biopharmaceuticals, Inc.
    Recruiting
    Last update posted :
    03/29/2024
    Initiation :
    07/15/2021
    Primary completion :
    07/31/2025
    Completion :
    12/31/2025
    BRAF • NF1 • RAF1
    |
    BRAF fusion • RAF1 amplification
    |
    Ojemda (tovorafenib) • pimasertib (AS703026)
    Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma (NCT05760586)
    Phase N/A
    Day One Biopharmaceuticals, Inc.
    Available
    Last update posted :
    01/31/2024
    BRAF
    |
    BRAF mutation
    |
    Ojemda (tovorafenib)
    A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY 1) (NCT04775485)
    Phase 2
    Day One Biopharmaceuticals, Inc.
    Recruiting
    Last update posted :
    12/27/2023
    Initiation :
    04/22/2021
    Primary completion :
    12/22/2022
    Completion :
    06/10/2024
    BRAF
    |
    Ojemda (tovorafenib)
    A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies (NCT02327169)
    Phase 1b
    Millennium Pharmaceuticals, Inc.
    Completed
    Last update posted :
    02/25/2020
    Initiation :
    01/14/2015
    Primary completion :
    07/02/2018
    Completion :
    07/02/2018
    KRAS • BRAF
    |
    BRAF mutation • KRAS exon 2 mutation
    |
    Erbitux (cetuximab) • paclitaxel • irinotecan • sapanisertib (CB-228) • Ojemda (tovorafenib) • alisertib (MLN8237)